Epigral Ltd Stock Falls to 52-Week Low of Rs.933.45 Amid Continued Downtrend

Recent Price Movement and Market Context

On 2 Feb 2026, Epigral Ltd’s share price touched an intraday low of Rs.933.45, closing with a day’s loss of 2.96%. This decline extended a two-day losing streak during which the stock has fallen by 9.93%. The stock’s performance today notably lagged behind the Specialty Chemicals sector, underperforming by 2.37%. Furthermore, Epigral is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum.

In contrast, the broader market showed resilience with the Sensex recovering sharply after a negative start, gaining 451.29 points to trade at 81,006.97, a 0.35% increase. Mega-cap stocks led this recovery, while the Sensex itself remains below its 50-day moving average, though the 50DMA is positioned above the 200DMA, indicating mixed medium-term market signals.

Long-Term Performance and Valuation

Epigral Ltd’s one-year stock performance has been notably weak, delivering a negative return of 47.63%, starkly contrasting with the Sensex’s positive 4.52% return over the same period. The stock’s 52-week high was Rs.2,114.30, highlighting the extent of the decline from its peak.

Over the last three years, Epigral has consistently underperformed the BSE500 index, reflecting challenges in sustaining growth and investor confidence. The company’s market capitalisation grade stands at 3, indicating a relatively modest market cap within its peer group.

Financial Performance Highlights

Epigral’s financial results have shown signs of strain in recent quarters. The company reported its lowest quarterly PBDIT at Rs.102.74 crores, indicating pressure on earnings before interest, depreciation, and taxes. Profit after tax (PAT) for the quarter stood at Rs.39.11 crores, reflecting a sharp decline of 61.1% compared to the average of the previous four quarters.

Interest expenses for the nine months ended December 2025 rose significantly by 43.93%, reaching Rs.56.16 crores. This increase in interest burden has contributed to the compression of net profitability. Over the past year, profits have declined by 2.9%, further underscoring the challenges faced by the company in maintaining earnings growth.

Despite these headwinds, the company’s operating profit has grown at a modest annual rate of 5.77% over the last five years, indicating some degree of long-term growth, albeit at a subdued pace relative to sector peers.

Valuation and Efficiency Metrics

Epigral Ltd exhibits a high return on capital employed (ROCE) of 23.19%, signalling efficient use of capital in generating earnings. The company also maintains a low debt-to-EBITDA ratio of 1.34 times, reflecting a strong ability to service its debt obligations.

Its enterprise value to capital employed ratio stands at a very attractive 1.8, suggesting that the stock is trading at a discount relative to its peers’ historical valuations. This valuation gap may be indicative of market concerns about the company’s near-term earnings trajectory and broader sector dynamics.

Shareholding and Sector Position

The majority shareholding in Epigral Ltd is held by promoters, providing a stable ownership structure. The company operates within the Specialty Chemicals sector, which has experienced mixed performance amid evolving market conditions.

Summary of Key Metrics

To summarise, Epigral Ltd’s current market position is characterised by a 52-week low price of Rs.933.45, a Mojo Score of 31.0, and a Mojo Grade of Sell, which was upgraded from Strong Sell on 26 Dec 2025. The stock’s recent performance has been below sector averages and broader market indices, with a notable decline in profitability and rising interest costs.

While the company demonstrates strong capital efficiency and manageable debt levels, its subdued growth rates and recent earnings contraction have weighed on investor sentiment. The stock’s valuation remains discounted relative to peers, reflecting the market’s cautious stance.

Market and Sector Outlook

The Specialty Chemicals sector continues to face a complex environment with varying performance across companies. Epigral Ltd’s recent price action and financial results highlight the challenges faced by smaller-cap players in maintaining growth momentum and profitability amidst competitive pressures and cost dynamics.

Meanwhile, the broader market’s recovery led by mega-cap stocks contrasts with the stock’s underperformance, emphasising the divergence in investor focus and sector rotation trends.

Unlock special upgrade rates for a limited period. Start Saving Now →